Candel Therapeutics Grants Inducement Stock Options to New General Counsel
Candel Therapeutics, Inc. announced the grant of stock options to Maria Ostrovsky in connection with her appointment as the company's General Counsel.
Stocks · News reference
Candel Therapeutics Announces Late-Breaking Abstract Acceptance for SITC 2026 Annual Meeting
Candel Therapeutics will present longitudinal immune-profiling data from its phase 2 PrTK05 clinical trial of aglatimagene besadenovec in localized prostate cancer at the SITC 2026 Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics, Inc. granted stock options to four new employees as an inducement for their employment.
Candel Therapeutics' Abstract From Its Phase 2 PrTK05 Clinical Study Of Aglatimagene Besadenovec Accepted For Presentation At Society For Immunotherapy Of Cancer’s 41st Annual Meeting
Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer
Candel Therapeutics announced that its phase 2 PrTK05 clinical trial data for aglatimagene besadenovec in localized prostate cancer has been accepted for poster presentation at the SITC 41st Annual Meeting in November 2026. The presentation will feature longitudinal immune-profiling, biodistribution, and viral shedding data from the trial combining aglatimagene with valacyclovir and radiation therapy.
Candel Therapeutics to Present at November Investor Conferences
Candel Therapeutics, Inc. announced that it will participate in upcoming investor conferences scheduled for November 2026.
Jefferies Initiates Coverage on Candel Therapeutics with Buy Rating
Jefferies analyst Maury Raycroft has initiated coverage on Candel Therapeutics with a Buy rating and a price target of $25.